RecruitingPHASE1, PHASE2NCT07239596

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Studying Acquired cystic disease-associated renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Intervention
SHR-8068;Adebrelimab ;Bevacizumab(drug)
Enrollment
139 target
Eligibility
18-75 years · All sexes
Timeline
20262030

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07239596 on ClinicalTrials.gov

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Acquired cystic disease-associated renal cell carcinoma

← Back to all trials